...
首页> 外文期刊>Malaria Journal >Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos
【24h】

Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos

机译:全国推荐的青蒿素联合蒿甲醚-去甲肾上腺素在老挝南部治疗单纯性恶性疟的功效

获取原文
           

摘要

Background The Lao Government changed the national policy for uncomplicated Plasmodium falciparum malaria from chloroquine to artemether-lumefantrine (AL) in 2005. Since then, no information on AL efficacy has been reported. With evidence of resistance to artemisinin derivatives in adjacent Cambodia, there has been a concern as to AL efficacy. Monitoring of AL efficacy would help the Lao Government to make decisions on appropriate malaria treatment. Methods The efficacy of a three-day, twice daily oral artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Xepon District, Savannakhet Province, southern Laos was studied over 42?days follow-up. This was part of a trial of thiamin supplementation in falciparum malaria. Results Of 630 patients with P. falciparum enrolled in the trial of thiamin treatment, 549 (87%, 357 children ≤15?years and 192 adults) were included in this study. The per protocol 42-day cure rates were 97% (524/541) [96% (337/352) for children and 99% (187/189) for adults, p?=?0.042]. By conventional intention-to-treat analysis, the 42-day cure rates adjusted for re-infection, were 97% (532/549) [96% (342/357) in children and 99% (190/192) in adults, p?=?0.042]. The proportion of patients who remained parasitaemic at day 1 after treatment was significantly higher in children [33% (116/356)] compared to adults [15% (28/192)] (p?
机译:背景信息老挝政府于2005年将国家简化了对恶性疟原虫疟疾的国家政策,从氯喹改为蒿甲醚-卢芬特林(AL)。此后,没有关于AL疗效的报道。有证据表明邻国柬埔寨对青蒿素衍生物有抗药性,因此人们对AL的疗效感到担​​忧。监测AL的疗效将有助于老挝政府就适当的疟疾治疗作出决定。方法在42天的随访中,研究了为期三天,每天两次的口服蒿甲醚-黄麻黄素治疗老挝南部萨凡纳赫特省Xepon区的单纯性恶性疟疾的疗效。这是补充硫胺素治疗恶性疟疾的试验的一部分。结果参加硫胺素治疗试验的630名恶性疟原虫患者中,包括549名(87%,≤15岁的357名儿童和192名成人)。按照方案的42天治愈率是97%(524/541)[儿童为96%(337/352),成人为99%(187/189),p≥0.042]。通过常规的意向性治疗分析,针对再次感染进行调整的42天治愈率是97%(532/549)[儿童为96%(342/357),成人为99%(190/192), p≥0.042]。儿童治疗后第一天仍保持寄生状态的患者比例[33%(116/356)]明显高于成人[15%(28/192)](p <0.001),只有一名成人患者在第2天有可检测到的寄生虫血症。没有严重的不良事件。据报告,治疗后的潜在副作用在成年人(32%)中比在儿童(15%)中更为普遍(p <0.001)。与治愈的患者相比,复发性感染的患者要年轻得多,平均发烧时间更长,中位的寄生虫清除时间更长。结论在老挝引进五年后,目前国家推荐的抗疟疾治疗方法(蒿甲醚-卢美他汀)对单纯性恶性疟疾的治疗仍然非常有效。如果应出现对青蒿素耐药的恶性疟原虫,应定期监测。试用注册ISRCTN85411059。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号